Wanted: Better Upstream Bioprocessing Technologies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Wanted: Better Upstream Bioprocessing Technologies
A recent industry survey shows keen interest in improving bioreactors and cell-culture media.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 7, Issue 7

Perfusion and batch-fed systems

Perfusion bioreactors appear to be positioned to become the next major revolution in bioprocessing and single-use equipment, with perfusion equipment on track to compete head-to-head with conventional batch-fed bioreactors even at commercial GMP scale. The study, however, showed that the industry's view of perfusion largely is dated.

Perfusion is not new. For example, perfusion bioreactors were widely used for hybridoma culture in the 1970s–1980s before antibody manufacture switched to batch-fed, mammalian-cell bioreactor manufacture of recombinant antibodies. Perfusion bioreactors were available from such companies as Endotronics, Cellex, Biosyn, and Biovest. Today, providers of perfusion bioreactors include FiberCell Systems and Zellwerk (marketed in the US by Glen Mills).

Nearly all current bioprocessing today involves batch-fed bioreactors. Perfusion involves continuous slow feeding and removal of spent media along with the desired product with the host cells retained within the bioreactor by being bound to bundles of capillary fibers or other membranes or retained in suspension in the bioreactor by special filters. While batch-fed bioreactors involve cells in dilute culture- media suspension, perfusion bioreactors grow cells at ≥100 to 1000 times higher concentration, with bioreactors commensurately smaller. Thus, using a small perfusion bioreactor over time with the same amount of culture media may match or beat the product output of a much larger batch-fed bioreactor. For example, FiberCell Systems reports it is developing desk-sized units that will have the equivalent recombinant-protein production capacity of conventional 2000–5000-L bioreactors. Also, ATMI recently launched iCellis, the first large-scale perfusion bioreactor.

Although perfusion appears to be a viable new product candidate, the BioPlan survey shows that industry knowledge and attitudes toward perfusion remain largely dated. Among a list of 17 problems commonly encountered in bioprocessing, respondents consistently had more serious concerns with perfusion than with batch-fed systems. These issues included process complexity (66.1% of respondents had serious concerns with perfusion systems compared with 4.9% for batch-fed) and contamination risks (63.9% had concerns with perfusion compared with 3.8% for batch-fed systems) (1). These and other concerns for perfusion already are being resolved as new bioreactors enter the market. As new products are launched in coming years, commercial-scale devices are likely to capture significant interest as new upstream solutions.

Eric Langer is president of BioPlan Associates, tel. 301.921.5979,
and a periodic contributor to Outsourcing Outlook.


1. E.A. Langer, 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates (Rockville, MD, April 2011), http://www.bioplanassociates.com/.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here